《新股表現》東曜藥業(01875.HK)暗盤收報6.13元 低上市價6.4%
根據輝立交易平台顯示,明天掛牌的東曜藥業(01875.HK)暗盤高開10.7%報7.25元欠承接,掉頭低見5.92元,收報6.13元,較上市價6.55元,低6.4%或0.42元,成交193萬股,涉資1,200萬元。
東曜是內地一間臨床階段仍未有盈利的生物製藥公司,致力於開發和商業化創新型腫瘤藥物及療法。是次上市共發售9,000萬股,並已引入3名基石投資者,包括控股股東晟德大藥廠、主要股東Vivo Capital及在台上市的年興紡織旗下年興維京群島,合共認購2,392.84萬股(禁售期六個月);10%公開發售獲近12倍超購,認購一手中籤率15%;股份以招股範圍(6.55-7.55元)下限定價,料集資淨額約5.11億元,主要用作為TAB008的進行中和計劃進行臨床試驗、註冊備案準備及潛在商業推出(包括銷售及營銷)提供資金、用作為研發中的其他在研產品提供資金,以及用於非項目特定資本開支等。上市獨家保薦人工銀國際融資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.